Oneview Healthcare (ASX:ONE) Research & Development: A$0.00 Mil (TTM As of Dec. 2025)


ASX:ONE Oneview Healthcare PLC ASX:ONE
42 GF Score
Price A$0.14
GF Value A$0.33
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Oneview Healthcare Research & Development?

Oneview Healthcare ASX:ONE -9.68% 42 Research & Development is A$0.00 Mil as of Dec. 2025. GuruFocus rates ASX:ONE with a GF Score™ of 42/100 and a GF Value™ of A$0.33 (Possible Value Trap). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Oneview Healthcare's Research & Development for the six months ended in Dec. 2025 was A$0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.00 Mil.

Oneview Healthcare  (ASX:ONE) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Oneview Healthcare Research & Development Related Terms

Oneview Healthcare Research & Development Historical Data

* Premium members only.

The historical data trend for Oneview Healthcare's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oneview Healthcare Research & Development Chart

Oneview Healthcare Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Oneview Healthcare Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ASX:ONE
42GF Score
Oneview Healthcare PLC ASX:ONE
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oneview Healthcare Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of A$0.00 Mil mean?
Oneview Healthcare (ASX:ONE) has a Research & Development of A$0.00 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Oneview Healthcare and its competitors.
Is Oneview Healthcare's Research & Development too high?
Oneview Healthcare's current Research & Development is A$0.00 Mil. Overall, Oneview Healthcare has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Oneview Healthcare's Research & Development compare to VEEV and BTSG?
Oneview Healthcare's Research & Development of A$0.00 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Oneview Healthcare and its competitors. Oneview Healthcare's current Research & Development is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oneview Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Oneview Healthcare (ASX:ONE) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.33, compared to a current price of A$0.14 — trading 57.6% below its estimated fair value. The current Research & Development is A$0.00 Mil. Oneview Healthcare's overall GF Score™ is 42/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Oneview Healthcare (ASX:ONE), the current Research & Development is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oneview Healthcare (ASX:ONE) Overvalued in 2026?

Based on GuruFocus' analysis, Oneview Healthcare stock appears to be undervalued. The current stock price of A$0.14 is trading 57.6% below its estimated GF Value™ of A$0.33. GuruFocus considers Oneview Healthcare to be Possible Value Trap.

Key valuation signals for ASX:ONE:

  • Research & Development: A$0.00 Mil
  • GF Value™: A$0.33 vs. price of A$0.14 (57.6% below fair value)
  • GF Score™: 42/100 with 5 warning signs

No single metric tells the full story. See the ASX:ONE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oneview Healthcare Business Description

Address Temple Road, 2nd Floor, Avoca Court, Blackrock Co, Dublin, IRL, A94 R7W3
Oneview Healthcare PLC provides patient engagement and clinical workflow technology solutions to healthcare facilities. It serves hospitals and healthcare systems, academic medical centers, and pediatric hospitals. Oneview Healthcare's Care Experience Platform (CXP) provides a unified set of digital tools in a single bedside solution and connects patients, families, and care teams with services, education, and information during hospital stays. The company operates in one reportable segment, which provides a patient engagement solution for the healthcare sector.
42GF Score

Get the complete analysis for ASX:ONE

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.14
Price
A$0.33
GF Value